Gilead appoints Andrew Dickinson as CFO

pharmafile | October 16, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November.

Dickinson currently serves as the company’s Executive Vice President of Corporate Development and Strategy and in his new role will become part of a senior leadership team reporting directly to Chairman and Chief Executive Officer Daniel O’Day.

Daniel O’Day commented: “Andy is an exceptional, highly strategic leader. In addition to his impressive business and financial acumen and broad experience, Andy possesses strong creativity and vision. This has been evident in the way Gilead has approached acquisitions and partnerships under Andy’s leadership.

“Over the past months, one of my key priorities has been to ensure we have an outstanding team of leaders to shape Gilead’s long-term success. I am pleased that with Andy’s appointment as CFO, we now have our full leadership team in place.”

Dickinson joined Gilead in 2016 where he transformed and expanded the kinds of transactions executed and implemented a broader and more strategic approach to deal making. He served as the architect of the company’s 2017 acquisition of Kite Pharma as well as the 10-year, global research collaboration with Galapagos NV announced earlier this year.

Dickinson himself, said: “It has been an incredible privilege to work at Gilead for the past three years and I am honoured to have the opportunity to serve as the company’s next CFO.

“I am looking forward to working with the talented teams across Gilead in this new role as we together seek to improve care for millions of people around the world who are in need of better treatment options.”

Dickson will replace Robin Washington, who currently serves and Chief Financial Officer and both will work together to ensure a smooth transition. Washington will remain at Gilead in an advisory capacity through the completion of the company’s reporting of 2019 financial results early next year.

Related Content

No items found

Latest content